Turn Therapeutics (NASDAQ:TTRX) Stock Bumped Up to Strong-Buy by Lucid Cap Mkts

Turn Therapeutics (NASDAQ:TTRX) was upgraded by Lucid Cap Mkts to a “strong-buy” rating in a note issued to investors on Thursday, Zacks reports.

Several other equities research analysts also recently issued reports on TTRX. Weiss Ratings downgraded Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 18th. WBB Securities reiterated a “sell” rating and set a $10.00 price objective on shares of Turn Therapeutics in a research note on Monday, September 14th. Wall Street Zen raised Turn Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, September 13th. LADENBURG THALM/SH SH upgraded Turn Therapeutics to a “strong-buy” rating in a research note on Monday, July 20th. Finally, Zacks Research raised Turn Therapeutics to a “hold” rating in a report on Tuesday, July 21st. Two equities research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $9.00.

Turn Therapeutics Stock Performance

NASDAQ TTRX opened at $13.26 on Thursday. The firm has a market cap of $394.99 million and a P/E ratio of -45.72. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 8.83. The company’s 50 day moving average is $10.60 and its 200-day moving average is $6.95. Turn Therapeutics has a 12-month low of $2.57 and a 12-month high of $26.50.

Turn Therapeutics (NASDAQ:TTRX) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.20) EPS for the quarter. Sell-side analysts predict that Turn Therapeutics will post -0.4 earnings per share for the current year.

Institutional Investors Weigh In On Turn Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Jefferies Financial Group Inc. bought a new position in Turn Therapeutics in the 2nd quarter worth about $119,000. Bank of America Corp DE bought a new stake in shares of Turn Therapeutics during the 2nd quarter valued at about $103,000. Ieq Capital LLC purchased a new position in shares of Turn Therapeutics during the second quarter worth about $1,660,000. BlackRock Inc. bought a new position in shares of Turn Therapeutics in the second quarter worth approximately $282,000. Finally, Bridgewater Advisors Inc. bought a new position in shares of Turn Therapeutics in the second quarter worth approximately $242,000.

About Turn Therapeutics

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.